Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of ...
Psyence Biomedical completes first site initiation visit for Phase IIb study of nature-derived psilocybin for Adjustment Disorder in Palliative Care, with patient screening to start soon and first subject expected in October.
Highlighted Terms
Related News
Psyence Group announces successful site initiation visit for Psyence Biomed's Phase IIb study of nature-derived psilocybin for Adjustment Disorder in Palliative Care in Australia, partnering with Fluence and iNGENū CRO. The trial will evaluate two doses of psilocybin against a low-dose comparator in 87 patients.
Psyence Biomedical Ltd. completed the first site initiation visit for its Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care. The study, supported by partnerships with Fluence and iNGENū CRO, will evaluate two therapeutic doses of psilocybin (10mg, 25mg) against a low-dose comparator (1mg) in 87 patients. Patient screening will commence soon, with the first subject expected to be randomized in October. Topline data is anticipated in the second half of 2025, potentially leading to a Phase III clinical program.
Psyence Biomedical completes first site initiation visit for Phase IIb study of nature-derived psilocybin for Adjustment Disorder in Palliative Care, with patient screening to start soon and first subject expected in October.